The TissueCypher assay is designed to identify patients with Barrett's esophagus who are at risk of progressing to esophageal cancer.

Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.

NEW YORK – Canadian point-of-care imaging firm MolecuLight on Monday announced that it has secured a $27.5 million investment from asset management firm Hayfin Capital Management.

Under the agreement, Sysmex will distribute and service in Canada Sentinel Diagnostics' SentiFit 270 and SentiFit 800 analyzers for fecal immunochemical testing.

NEW YORK – Anbio Biotechnology filed this week a preliminary prospectus for an initial public offering on the Nasdaq exchange of 1.6 million shares at an anticipated offering price in the range of $5 ...